IL6 and cancer: The IL6-JAK-STAT3 pathway is always aberrantly hyperactivated in many cancer types (Wang and Sun, 2014; Zhang et al., 2016; Chiang et al., 2020; Pan et al., 2020), and this phenomenon is often associated with poor outcomes (Kusaba et al., 2005; Macha et al., 2011; Chen et al., 2013).